Latest Breaking News On - Kevin isett - Page 1 : comparemela.com

Valley News - The Upper Valley has become a booming hub for biotech firms

In 2001, when Phil Ferneau and his partners were launching a venture capital firm focused on New Hampshire startups, they met with several academics at Dartmouth College. Ferneau had been an advocate for converting academic research into viable.

New hampshireUnited statesThayer school of engineeringUnited kingdomSan franciscoPhil ferneauTracey hutchinsJake rederTillman gerngrossJulie demersWarren kettCharles hutchinsonMichael fangerKevin isettDane wittrupGeisel school of medicine at dartmouth

How the Upper Valley Became a Bi

In 2001, when Phil Ferneau and his partners were launching a venture capital firm focused on NH startups, they met with several academics at Dartmouth College. Ferneau had been an advocate for converting academic research into viable companies in his.

United kingdomUnited statesSan franciscoPhil ferneauTracey hutchinsJake rederTillman gerngrossCharles hutchinsonJulie demersWarren kettMichael fangerDane wittrupKevin isettGeisel school of medicine at dartmouthDartmouth tuck school of businessDartmouth college

Biotech startup sells for $150M

Biotech startup sells for $150M
concordmonitor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from concordmonitor.com Daily Mail and Mail on Sunday newspapers.

United statesSondra newmanTillman gerngrossTony huntWarren kettNavigo gmbKevin isettDartmouth collegeAvitide incThayer school of engineeringRepligen corpThayer schoolDartmouth regional technology centerCenterra resource parkUpper valleyNavigo gmbh

Valley News - Biotech startup sells for $150 million

Valley News - Biotech startup sells for $150 million
vnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vnews.com Daily Mail and Mail on Sunday newspapers.

Avitide Finalizes Development of AVIPure®-COV2S, an Affinity Purification Resin for COVID-19 Vaccines

Share this article Share this article LEBANON, N.H., Feb. 4, 2021 /PRNewswire/ Avitide, Inc. the industry leader in the discovery and development of affinity purification chromatography resins, announced that it has finalized the development of an affinity bioprocess resin for the purification of recombinant COVID-19 vaccines. The AVIPure ®-COV2S resin delivers outstanding performance as a capture resin for the majority of recombinant COVID-19 vaccines. The AVIPure ®-COV2S resin is based on an affinity ligand that is highly selective to the receptor binding domain within the SARS-CoV-2 virus spike protein. The receptor binding domain is a central component within all recombinant COVID-19 vaccine developers strategies to elicit protective immune responses. Given the selectivity of the AVIPure

Nick russellWarren kettKevin isettPrnewswire avitide incAvitide incHead of business developmentChief scientificChief executiveநிக் ரஸ்ஸல்வாரன் கெட்தலை ஆஃப் வணிக வளர்ச்சிதலைமை அறிவியல்தலைமை நிர்வாகி